Q2 2017 13F Holders as of 30 Jun 2017
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
20,648,023
-
Share change
-
-407,397
-
Total reported value
-
$2,499,803,066
-
Put/Call ratio
-
57%
-
Price per share
-
$121.07
-
Number of holders
-
164
-
Value change
-
-$48,280,917
-
Number of buys
-
90
-
Number of sells
-
62
Institutional Holders of INTERCEPT PHARMACEUTICALS IN - COM (ICPT) as of Q2 2017
As of 30 Jun 2017,
INTERCEPT PHARMACEUTICALS IN - COM (ICPT) was held by
164 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
20,648,023 shares.
The largest 10 holders included
FMR LLC, AMERIPRISE FINANCIAL INC, Carmignac Gestion, Capital World Investors, VANGUARD GROUP INC, BlackRock Inc., ORBIMED ADVISORS LLC, STATE STREET CORP, CITADEL ADVISORS LLC, and JPMORGAN CHASE & CO.
This page lists
164
institutional shareholders reporting positions in this security
for the Q2 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.